The company's protein engineering platform is designed for multispecific therapies, addressing the limitations of existing cancer, autoimmune, and other disease therapies. Tentarix's therapeutics leverage synthetic biology to create multispecific binding molecules and combined bioactivities based on fully human antibody variable domains, providing clinicians with antibody-based multifunctional biotherapeutics that achieve unprecedented specificity and unique activity. The company is leading a fundamental change in the methods of discovery and engineering of multi-specific biologics, with a $50 million Series A funding to support its mission.